Pfizer shares vaccine timeline for children under 12 years old
Pfizer discussed its plans to expand the availability of its COVID-19 vaccine this fall to include children that are 6-months-old to 11-years-old during an on-camera investor conference Tuesday.
Pfizer’s Chief Financial Officer Frank D’Amelio said the company projects to have safety and efficacy data for children 5 to 11-years-old “by the end of September.” Pfizer expects to file the data with the FDA in “early October.”
D’Amelio said that in the weeks following the submission, the company will file similar data for children between the ages of 6 months to 5-years-old. Phase three studies are currently underway for children in those age groups.
“We would expect to have similar data for children between the ages of 6 months and 5-years-old, that we would file with the FDA, I'll call it, in the weeks shortly thereafter the filing of the data for the 5 to the 11-year-olds,” D’Amelio said. “And then obviously, all of that depends on having a positive outcome on the data.”
In the meeting, he also doubled down in support of booster shots saying the company “believes that there’s clearly benefit” to “maintaining high levels of protection with a third dose.”
-ABC News’ Arielle Mitropoulos